WO2001032916A2 - Automated lysophospholipid assay and methods of detecting cancer - Google Patents
Automated lysophospholipid assay and methods of detecting cancer Download PDFInfo
- Publication number
- WO2001032916A2 WO2001032916A2 PCT/US2000/030280 US0030280W WO0132916A2 WO 2001032916 A2 WO2001032916 A2 WO 2001032916A2 US 0030280 W US0030280 W US 0030280W WO 0132916 A2 WO0132916 A2 WO 0132916A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- assay
- lysophospholipid
- sample
- concentration
- solution
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
- C12Q1/28—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving peroxidase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
- C12Q1/32—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving dehydrogenase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
- G01N2405/04—Phospholipids, i.e. phosphoglycerides
Definitions
- Cancer is a major cause of death in the United States exceeded only by heart disease. In 1999 an estimated 563,100 Americans will die of cancer. Moreover, approximately 1 ,221 ,800 new cases of cancer are predicted in the US for the year.
- the major solid tumors in the US include those of the lung, breast, colon, prostate, and ovaries.
- Lung cancer is the most common cause of cancer death for both sexes with almost 159,000 lung cancer related deaths expected in 1999. Total colorectal cancer- related deaths are second only to lung cancer with over 56,000 expected.
- Breast cancer continues to be the most common form of cancer present in females in the US with an estimated 176,300 new cases projected to be diagnosed during the year. In males, prostate cancer is the most common form of cancer with projections of 179,300 new cases diagnosed and 37,000 prostate cancer related deaths occurring during 1999.
- Ovarian cancer is the leading cause of gynecologic death.
- Procedures used for detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, or determining predisposition of diseases or conditions of these organs are of critical importance to the outcome of the patients. It is generally accepted that detection of a solid tumor at an early stage dramatically reduces disease-related mortality. For example, patients diagnosed with localized prostate cancer have greater than a 90% five-year relative survival rate compared to a survival rate of 25 to 31% for patients diagnosed with distant metastasis. Staging of the cancer is performed after its diagnosis is confirmed because it is a strong predictor of patient outcome and greatly influences patient treatment. In addition, patients are monitored after primary therapy to detect persistent disease and to detect early distant metastasis.
- Women with gynecological cancers are especially in need of an accurate and early diagnostic, especially those with ovarian cancer.
- Patients with ovarian cancer have the highest mortality rate among women with gynecologic cancers, with an estimated 14,500 deaths from ovarian cancer in 1998 in the Unites States. More than two thirds of patients with ovarian cancer have widespread metastatic disease at initial diagnosis.
- the outlook for women with advanced disease remains poor, with a 5-year survival rate of no more than 15%. This dismal outcome is due, at least in part, to the failure to detect the disease at stage I, when the long-term survival rate may approach 90%.
- Methods for earlier detection are essential to improve prognosis and overall survival of patients with ovarian cancer.
- LPA lysophosphatidic acid
- Xu et al "Lysophosphatidic Acid as a Potential Biomarker for Ovarian and Other Gynecological Cancers", JAMA , 1998 Aug.26;280 (8):719-723.
- LPA measurement can be used as a diagnostic to detect carcinomas and, especially to detect early stage ovarian cancer.
- the prior art generally describes a method of detecting LPA as follows. The lysophospholipid, such as LPA, is incubated with lysophospholipase to produce glycerol- 3-phosphate (G-3-P).
- G-3-P is then converted to dihydroxyacetone phosphate and hydrogen peroxide using G-3-P oxidase in the presence of oxygen and water.
- G-3-P dehydrogenase converts dihydroxyacetone phosphate back to G-3-P and oxidizes NADH to NAD.
- the measurement of hydrogen peroxide correlates with LPA levels. Specifically, optical absorbance at 505nm indicates an accumulation of hydrogen peroxide and, thus, the presence of LPA in the test sample.
- the prior art teaches a multi-step process in order to measure LPA concentrations.
- the prior art procedure for measuring LPA in order to detect cancer involves an initial liquid: liquid organic phase extraction using a number of reagents in a multi-step procedure to a biological sample such as whole blood is collected from a patient.
- a biological sample such as whole blood is collected from a patient.
- the sample usually plasma
- the analyte is extracted from the sample and reconstituted to its original concentration in a buffer compatible with the subsequent assay.
- the plasma sample is first vortexed with chloroform:methanol to precipitate protein. After centirfugation to pellet the protein, more chloroform and tris buffer are added and the mixture again vortexed and centrifuged.
- the organic layer is then mixed with a small amount of an aqueous tris buffer containing detergent and calcium chloride, and the solvent evaporated off, leaving the residue which is stored at -80° C until reconstitution and assay. Because of the numerous pipetting steps and multiple extractions there is great potential for loss and accumulation of error in this procedure. This, along with the use of the toxic, volatile solvent chloroform, greatly complicate its use in a clinical laboratory.
- G3P by exposure to a lysophospholipase for 60 minutes at 37° C.
- the G3P is then treated with a mixture of enzymes which consumes NADH and produces hydrogen peroxide at a rate dependent on the G3P concentration.
- One of the enzymes, G3P oxidase oxidizes G3P to DHAP with the evolution of hydrogen peroxide.
- the other enzyme, Glycerophosphate degydrogenase converts the DHAP back to G3P, this reverse reaction being driven by the conversion of NADH to NAD.
- the rate of this cycling reaction i.e. the rate at which hydrogen peroxide is produced and NADH converted to NAD, is dependent (all other variables being held constant) on the concentration of G3P.
- the extent of reaction may be determined in either of two ways.
- the concentration of NADH may be monitored either continuously or at the end of the incubation, and its decrease determined by measuring the loss of absorbance at 340 nm.
- the amount of hydrogen peroxide generated may be measured by a colorimetric reaction using perxidase and a colorigenic substrate
- the disappearance (oxidation) of NADH is then monitored spectrophotometrically at OD 40 (i.e. disappearance of OD 340 ).
- the production of hydrogen peroxide may be measured, for example colorimetrically by fluorometry or chemiluminescence.
- any of a number of chromogenic substrates may be used including 4-aminoantipyrine (AAP), pyrogallol, 2- (2'-Azinobis (3-ethylbenzthiazoline-sulfonic acid) (ABTS) and 3,3',5,5'- tetramethylbernzidine) (TMB).
- this complicated LPA detection process calls for many separate reagents to be used in many separate steps in a specified chronological order. Further, several of the reagents must be mixed together just prior to use. Due to this complexity, it is difficult, if not impossible, to put this LPA detection assay on an automated format and, the lengthy incubation periods required for each step make it difficult to use this assay in a clinical format.
- the reason for the aforementioned steps and multi-reagent format is that it was previously thought that a complete conversion of LPA to G3P, prior to the cycling reaction, was necessary in order to obtain an accurate measurement.
- the inventors have combined hydrolysis and cycling compounds into a single reagent and further optimized the assay such that the reaction time can be reduced from over 2 hours to 15 minutes or less. Specifically, the inventors have combined the lipase, G3P oxidase, G3P dehydrogenase, CaCl 2 and Tris into a single reagent stable at 4° C. The NADH is stored separately at -20° C.
- the inventors found, quite unexpected, that the generation of G-3-P from LPA did not interfere with the cycling steps performed by G-3-P oxidase and G-3-P-dehydrogenase and that measurements were highly accurate. Short incubation periods are crucial to automating an assay as well as providing an effective assay format to clinicians, both of which this invention allows.
- sample handling remains critical. Blood sampling must be collected so as to prevent lysis of platelets, centrifuged sufficiently to remove platelets as well as erythrocytes. If not tested promptly after collection/centrifugation, they must be frozen at -20° C to prevent changes in LPA concentration. Additionally, if free G3P is present, it may be necessary to measure this separately and subtract to get actual LPA concentration.
- Still another problem in the prior art involves the lack of stabilized detection reagents, i.e. peroxidase and chromophore precursor solutions.
- the components of this formulation were stored separately and then mixed just minutes prior to use. Again, this multi-step format makes automation of this assay impossible, or impractical.
- What the present inventors have discovered is a combined formulation of peroxidase and chromophore precursor solutions that are stable at both room temperature and 37° C. Specifically, the inventors have combined the chromophore precursors i.e. phenol, phenol derivatives and phenazones together as one stable reagent.
- the inventors have added sodium azide (an antimicrobial) TritonX-100, and FG-10 anti-foam to further improved stability and shelf-life. Also, with the aforementioned improved formulation, the inventors found the chromophore precursor solution also stabilizes added HRPO, further reducing reagent number. The improved simplicity and stability enhances the assay considerably and makes automation possible and reliable.
- the present invention relates to an improved enzymatic diagnostic assay to detect carcinoma by measuring various lysophospholipids, including lysophosphatidic acid (LPA), in a patient.
- this assay measures the human plasma level of LPA in an automated format with a minimal number of reagents and with reduced incubation periods.
- the present invention comprises several additional technical improvements to the current LPA assays disclosed in the prior art as described below.
- the inventors have also shown that the cross-reactivity of LPC is significantly reduced in their improved single step assay versus the prior art multi-step assay. This completely eliminates the need for the extraction step currently used.
- the inventors also illustrate that the hydrolysis and cycling enzymes and related solutions could be combined and that this single reagent remained stable and efficacious.
- the inventors have shown that the stability of the LPA calibrators could be significantly improved by eliminating calcium, previously thought to be essential to the calibrator's efficacy, from the calibrator matrix.
- the inventors have formulated an LPA assay in which unextracted plasma is actually the sample.
- the inventors have further shown an improved formulation of a detection reagent, which contains both peroxidase and chromophore precursors, that has significantly improved stability compared with the prior art reagents.
- the present invention not only combines these precursors into a single reagent format, but also stabilizes these reagents so that they are efficacious at room temperature, thereby eliminating the need for refrigeration and further lengthening shelf-life. This also allows simplification of the assay and enables it to be put onto an automated format.
- the inventors have actually automated the assay and have incorporated it onto an automated machine by incorporation of a fluorophore that enables conversion of the assay from an absorbance readout to a fluorescence readout.
- This fluorescent read out has a higher sensitivity than the prior art colorgenic method.
- the invention differs from prior art due to improved assay specificity, improved formulation stability, the elimination of numerous steps, reduced incubation time of the assay and actual assay automation. Also, the present invention differs in that it eliminates the extraction step and can use plasma as the actual sample.
- the lysophospholipase used in this assay can be any lipase that hydrolyzes the fatty acids (ester bonds) from either position 1 or 2 of lysoglycerophospholipids (i.e. sn-1 or sn-2 positions).
- examples include phospholipase B, phospholipase C, phospholipase D, lysophospholipase, phospholipase Aj, and phospholipase A , lecithinase B and lysolecithinase.
- Cycling enzymes used are any enzymes or combination of enzymes used to convert the glycerol -3-phosphate (G3P) intermediate to and from DHP and in the process increase the production of hydrogen peroxide, which is, preferably, the actual species that is detected.
- the two enzymes that are preferred are glycerol-3-phosphate oxidase which converts G3P to dihydroxyacetone phosphate (hydrogen peroxide is also generated in this step) and glycerol-phosphate dehydrogenase, which in the presence of NADH, converts the dihydroxyacetone phosphate back to G3P.
- G3P then goes through the same cycle generating additional hydrogen peroxide.
- cycling enzymes which can be used include serine dehydrogenase, serine deaminase, aldehyde dehydrogenase, ethanolamine deaminase, glycerokinase and glycerol dehydrogenase.
- the NADH is preferably stabilized, and the methods to stabilize NADH are described in the U. S. Patent 4,704,365, issued November 3, 1987 entitled “Composition and Method for Stabilization of Dinucleotides", herein incorporated by reference.
- the formulation described includes propylene glycol (polyhydroxyl alkyl solvent) at 50 %, boric acid and buffers.
- this patent discloses a reduced dinucleotide, preferably nicotinamide adenine dinucleotide (NADH), stabilized in an aqueous base liquid containing propylene glycol, boric acid and a buffer capable of buffering within a pH range of 8-11.
- the stabilized liquid contains greater than 50% (v/v) water.
- the remaining volume contains propylene glycol, which has been chemically treated to remove oxidants.
- the accuracy of this stabilizer is dependent on pH and the amount of glycerol as well as the sample volume.
- the hydrolysis/cycling mixture may also contain compounds which prevent degradation or production of lysophospholipids.
- Reagents for inhibiting production or hydrolysis of lysophospholipids include specific PLA2 inhibitors such as Aristolic Acid
- HELSS Hydroenol lactone suicide substrate, Biomol
- phosphodiesterase inhibitors such as IBMX (3-Isobutyl-l-methylxanthine, CalBiochem, La Jolla, CA); Ro-20-1724 (CalBiochem); Zaprinast (CalBiochem) and Pentoxifylline (CalBiochem); general protease inhibitors such as E-64 (trans-Epoxysuccinyl-L-leucylamido-(4- guanidino)butane, Sigma); leupeptin (Sigma); pepstatin A (Sigma); TPCK (N-tosyl-L- phenylalanine chloromethyl ketone, Sigma); PMSF (Phenylmethanesulfonyl fluoride, Sigma); benzamidine (Sigma) and 1,10-phenanthroline (Sigma); organic solvents including chloroform and methanol; detergents such as SDS; proteases that would degrade phospholipases
- the peroxidase solution contains peroxidase which is a hemoprotein catalyzing the oxidation by hydrogen peroxide of a number of substrates such as ascorbate, ferrocyanide, cytochrome c and the leuco form of many dyes.
- peroxidases are heme-binding enzymes that carry out a variety of biosynthetic and degradative functions using hydrogen peroxide as the electron acceptor.
- the function of the peroxidase is to catalyze the reaction of a suitable substrate to a detectable colored oxidized state species.
- Examples for a liquid assay include 3,3',5,5'-tetramethylbenzidine, 5-aminosalicylic acid (5AS), o-dianisidine, o-toluidine, o-phyeylenediamine, 2,2'-azinodi-(3- ethylbenzothiazoline-6-sulfonate) (ABTS) and those for a strip assay include 3,3'- diaminobenzidine (DAB), 3-amino-90-ethylcarbazole, 4-chloro-l-naphthol, 3,4- diamihnotoluene, 4,5-dimethyl-l,2-phenylenediamine, 4-chloro-l,2-phenylenediamine, 4,5-dichloro- 1 ,2-phenylenediamine.
- DAB 3,3'- diaminobenzidine
- DAB 3,3'- diaminobenzidine
- DAB 3-amino-90-ethyl
- the chromophore precursor solutions are the mixtures of compounds, that when oxidized, result in color. Any chromophore that develops a color that corresponds to the spectra of the fluorophore partner could be used in this technology. In other words, the preferred chromophore must be able to absorb light resulting in an attenuation of the fluorescence of the fluorphore used in the assay.
- the chromophore precursors act as electron donors and as they donate electrons, they are oxidized and thereby generate color.
- Fluorescent compounds are those compounds that when irradiated with UV or visible light, re-emit some of this light as longer wavelength light.
- the fluorescent compounds in the present invention are used to measure, via the Radiant Energy Attenuation (REA) method, the amount of signal generated.
- Alternative fluorescent compounds that could be used include those that are characterized by excitation and/or emission spectra that coincide with the absorption spectra of the generated chromophores.
- the generic REA method is better described in US Patent No. 4,495,293, issued January 22, 1985, entitled “Fluorometric Assay", herein incorporated by reference.
- this patent provides a method to fluorometrically determine a ligand in an assay solution containing the ligand, reagent system and a fluorescer wherein the intensity of the fluorescer emitted by the assay solution is related to the change in the transmittive properties of the assay solution produced by the interaction of the ligand to be determined and a reagent system capable of producing a change in the transmittive properties of the assay solution in the presence of the ligand.
- novel reagent compositions are provided which may be utilized to either spectrophotometrically or fluorometrically determine the concentration of a ligand in an assay solution.
- fluorphores examples include R-Phycoerythrin, TexasRed, Oregon Green, Fluorescein, Rhodamine Red, Tetramethylrhodamine, BODIPY FL, BODIPY TR, BODIPY TMR, YOYO-f, DAPI, Indo-1. cascade Blue, Fura-2, Amino methylcoumariln, Carboxy-Snarf, Lucifer Yellow, dansyl Derivitive.
- Cations contemplated in this invention are positively charged ions such as Na + , Ca ⁇ , Zn ++ , etc. They are used in the present invention to activate the glycerol-3- phosphate oxidase and any cation which activates glycerol-3 -phosphate oxidase is suitable. Others include those disclosed in Table 1.
- This Table illustrates the effect of metal ions on 1-a-glycerophosphate oxidase activity.
- 1-a-Glycerophosphate oxidase activity was measured in 1 mM potassium phosphate buffer, pH 7.0, and at 10 mM DL-a-glycerophosphate in the presence of the salts below by the peroxidase-linked system described under "Experimental Procedures". Effector L-a-Glycerophosphast Activation oxidase activity
- Chelators contemplated within the scope of this invention are multidentritic species (e.g. citrate, EDTA, EGTA) that bind to positively charged metal ions. Chelators may preferably be used to stabilize calibrators or to temporarily lower the availability of divalent cations in our system.
- multidentritic species e.g. citrate, EDTA, EGTA
- Chelators may preferably be used to stabilize calibrators or to temporarily lower the availability of divalent cations in our system.
- Phenol and phenazones are used as electron donors. Phenol as defined is hydroxybenzene sometimes referred to as carbolic acid. Derivitives would include compounds that have substituants on the positions of the benzene other than at the phenolic hydroxyl. Examples of phenazones include antipyrenes.
- LPA is the compound preferably detected, but other lysohospholipids are also contemplated within the scope of this invention in order to detect cancer, including but not limited to LysoPC, lysophosphatidyl serine (LysoPS), lysophosphatidyl inositol
- LysoPI lysophosphatidyl ethanolamine
- LysoPG lysophosphatidyl glycerol
- test kits useful for detecting LPA in a test sample comprise a container containing the necessary enzymes and other reagents for conducting the assay described herein.
- These test kits further comprise containers with tools useful for collecting test samples (such as, for example, food, urine, saliva and stool).
- tools include lancets and absorbent paper or cloth for collecting and stabilizing blood; swabs for collecting and stabilizing saliva; and cups for collecting and stabilizing urine or stool samples.
- Collection materials such as papers, cloths, swabs, cups, and the like, may optionally be treated to avoid denaturation or irreversible adsorption of the sample.
- the collection materials also may be treated with or contain preservatives, stabilizers or antimicrobial agents to help maintain the integrity of the specimens.
- the diseases correlated with altered concentrations of these lysophospholipids include conditions associated with platelet activation such as, inflammatory conditions.
- Altered phospholipid metabolism has been reported in many diseases and can lead to altered lysophospholipid and phospholipid levels in biological fluids, such as blood.
- diseases include, but are not limited to, Alzheimer's, diabetes, heart disease, ischemia, liver disease, lung disease, malaria, muscular dystrophy, Parkinson ' s, sickle cell anemia, and various cancers.
- defective cellular functions may contribute to changes in levels of phospholipids.
- Other diseases include bleeding disorders including those associated with abnormal platelet function resulting in coagulopathy.
- This example illustrates how an LPA assay can be reduced to only two steps and only two reagents.
- Lysophospholipase was combined with the cycling enzymes (i.e. glycerol-3- phosphate oxidase and glycerophosphate dehydrogenase) and NADH to form one reagent in the following way.
- cycling enzymes i.e. glycerol-3- phosphate oxidase and glycerophosphate dehydrogenase
- NADH NADH
- One hundred uL's of lysophosphatidic acid (Atairgin, Irvine CA) calibrators were added to the wells of a 96 well microtiter plate.
- Figure 1 A shows the results as an absorbance read while Figure IB shows that the results can also be read as fluoresence at 520 ran by incorporation of fluorescein in to the chromaphore mixture and utilizing the REA ("Radiant Energy Attenuation") method.
- the fluorescent readout has improved sensitivity as compared to the absorbance read-out.
- Novel Calibrators LPA calibrators were prepared as in the prior art by adding LPA (Sigma) to 2.5%
- Triton X-100 50mM CaCl 2. 50 mM Tris, pH 8.0. Novel calibrators were prepared using the same solution but only this time the calcium chloride was omitted. Calibrators were then stored for approximately 72 hours at both room temperature and 4° C. After 72 hours fresh calibrators were prepared (+/-) calcium. The fresh and stored calibrators were then evaluated in the LPA assay using the microtiter format as follows. One hundred uL of sample was added to the wells of a microtiter plate.
- the REA Chromophore/Fluorophore (C/F) reagent that contained glycine 1.0M;
- this aspect of the invention is critical in achieving an automated assay and incorporate it onto an automated machine, such as an Abbott Imx.
- One-Step Assay vs. Multi-Step Assay Comparison A comparison between the prior art two step (a separate lipase digestion prior to a combined lipase/cycling) microtiter format and a one step lipase/ cycling format was made. The sample size, incubation times and reagent quantities were kept identical so that a direct comparison can be properly made.
- Reagent A that contained lysophospholipase at 5 U/mL, glycerol dehydrogenase at 34 U/mL and glycerol oxidase at 134 U/mL in 10 mM calcium chloride, 50 mM Tris pH 8.
- Reagent B that contained 25 mM NADH in 50mM Tris pH 8.
- Reagent C similar to reagent A, but also containing
- Lysophosphatidic acid (LPA, Atairgin, Irvine CA) calibrators were added in duplicate to the wells of a 96 well microtiter plate.
- One hundred uL's of reagent A was added to the calibrators.
- the plates were mixed, covered and incubated for 15 minutes at 37° C.
- 50 ul's of reagent B was added to the wells.
- the addition of this reagent initiated the cycling.
- the plates were mixed then incubated for another 15 minutes at 37° C.
- Fifty uL's of the color development reagent (D) was added to all wells. The contents of the wells were mixed and the absorbances at 490 nm were read. The results are shown in Figure 5.
- Novel Assay Fifty uL's of Lysophosphatidic acid (LPA, Atairgin, Irvine CA) calibrators were added in duplicate to the wells of a 96 well microtiter plate. One hundred 100 uL's of reagent C was added. The plates were mixed, covered and incubated for 30 minutes at 37° C. Following this incubation 50 uL's of 50mM Tris pH 8.0 was added to the wells to adjust the volume to be the same as the prior art. Fifty uL's of the color development reagent (D) was added to all wells. The contents of the wells were mixed and the absorbances at 490 nm were read. The results shown in Figure 5 demonstrate the enhanced performance of the single step (Novel Assay) format relative to the two step prior art format that utilizes a separate lipase digestion.
- LPA Lysophosphatidic acid
- the novel REA chromophore/fluorophore (C/F) reagent contained glycine, 0.1 M; 3,5-dichloro-2- hydroxy benzensulfonic acid, 0.22M; 4 aminoantipyrene, 0.05M; dimethyl sulfoxide
- the prior art color development solution contained 0.5% 3,5-dichloro-2-hydroxy benzenesulfonic acid, 0.15% 4 aminoantipyrene, in 50 mM Tris pH 8.0.
- a HRPO solution (2500 U/mL) was added.
- IMx Instrument Automated Assay for LPA using IMx Instrument.
- the IMx instrument was designed to perform immunoassays in both microparticle and fluorescence polarization formats.
- the fluorescence polarization format can be adapted to perform "Radiative Attenuation Assay", which permits measurements based on optical absorbance.
- peroxidase and appropriate dyes - fluorescein and a colorigenic peroxidase substrate for example — to the mixture of Example 1 after the cycling reaction has proceeded to a sufficient degree the concentration of G3P, and therefore, sample LPA can be determined.
- Lipase hydrolvsisVCvcling Enzyme Reagent: lU/mL lysophospholipase, 200U/mL glycerophosphate dehydrogenase, 500uL glycerol-3 -phosphate oxidase, 40mM calcium chloride, 50mM Tris, 5mM sodium benzoate, 20% glycerol pH 8.0.
- Chromophore/Fluorophore Reagent 220mM 3,5 dichloro-2-hydroxy benzene sulfonic acid, 50mM 4-aminoantipyrene, lOOmM glycine, 4.5uM Fluorescein, 0.1 % sodium azide, 5.4% Triton X 100, 50% dimethyl sulfoxide, pH 8.5.
- HRPO Mixture 20U/mL horseradish peroxidase in 50mM tris pH 8.0.
- NADH Solution 1.5mM NADH in 50mM tris pH 8.0.
- a plasma sample can be prepared by the following method. Blood is collected in presence of a stabilizer such as EDTA or citrate. It is then centrifuged sufficiently to sediment erythrocytes and platelets (15 min at 3000XG) at 4°
- the mixture is incubated for 4 min then the fluorescence intensity is measured and immediately thereafter 20uL Chromophore/FIuorphore Reagent, 40uL HRPO mixture and 340uL line diluent are added.
- the mixture is incubated an additional 4 min during which the color is formed.
- the fluorescence intensity is measured again and the data transferred to a file for analysis.
- the ratio of the final fluorescence intensity to the initial fluorescence intensity decreases with increasing peroxide-generated color, and so can be used with appropriate calibrators to determine the amount of glycerol-3 -phosphate, and by extension the amount of LPA originally in the sample.
- the LPA does not react and only the free glycerol-3 -phosphate is measured.
- performing this assay both with and without lysophospholipase can provide the information needed to determine the actual LPA concentration.
- Table 2 shows the results of applying the above protocol to LPA standards ranging from 0 to 5uM. Initial and final fluorescence intensities and their ratio are shown along with the LPA concentration of the sample. The first 12 positions are duplicates of LPA standards in buffer, then replicates of 4 each of the zero and 2.0 uM standards. A 4-parameter log-logit curve fitting algorithm was used with these results to generate the curve in Figure 7.
- the standards AS 1 and AS 1 extracted are also measured.
- the LPA concentration measured for AS1 extracted is 0.53 uM, consistent with values determined using the microtiter format.
- the LPA concentration of the unextracted sample is 2.04 uM, about 4-fold higher than the extracted sample.
- LPC cross-reactivity is ruled out as a cause for reasons shown in Table 3. Most likely, the difference results from losses of LPA during the extraction process.
- Table 3 shows the application of the method to human plasma. Blood collected from normal volunteers in EDTA tubes was cooled in an ice bath immediately after collection. Within 80 min of collection it was centrifuged 15 min at 3000XG in a refrigerated centrifuge at 4° C.
- Table 4 shows the effect of sample handling and storage, and demonstrates that lysophosphatidylcholine, which interferes in the microtiter formatted assay, does not interfere in the IMx configured assay if samples are stored at -20° C.
- 500uL portions of the clear supernate were subjected to the following treatments, then aliquoted and stored as above at -20° C, 4° C and room temperature: Set B: no treatment
- Set C 2.0uL sample buffer (2.5% Triton X 100 in 50mM tris pH 8.0) added to 500uL clear plasma.
- the LPC spiked sample shows an increasing signal for LPA.
- a possible explanation is the presence of a phospholipase C activity in the plasma, which cleaves choline from LPC, leaving LPA.
- This assay can also be formatted on a strip. Specifically, whole blood is collected in the presence of a stabilizer, such as EDTA or citrate. It is then placed on a strip, which wicks the plasma away from the solid components. The plasma, preferably, passes through a portion of the strip containing calcium and the solid components are removed by continued passage through the strip.
- the lipase and cycling enzymes are located downstream on a conjugate pad along with detection reagents or labels.
- Example 7 This is similar to Example 7 (above) except the peroxidase and color generating reagents are combined into a single reagent, simplifying the assay.
- Lipase (hydrolysis)/Cycling lU/mL lysophospholipase, 200U/mL glycerophosphate dehydrogenase, 500U/mL glycerol-3-phosphate oxidase, 40mM calcium chloride, 50mM tris, 5mM sodium benzoate, 20% glycerol pH 8.0.
- Chromophore/Fluorophore/HRPO Mixture 20U/mL horseradish peroxidase, 220mM 3,5-dichloro-2-hydroxy benzene sulfonic acid, 50mM 4-aminoantipyrene, lOOmM glycine, 4.5uM Fluorescein, 0.1% sodium azide, 5.4% Triton X 100, 50% dimethylsulfoxide, pH 8.5.
- NADH solution 1.5mM NADH in 50mM Tris pH 8.0.
- Protocol lOOuL NADH solution, 5uL sample and 20uL Lipase/Cycling Enzyme reagent are aspirated by the sample probe. 70uL of this is dispensed to the cuvette and the remaining NADH reagent in the probe dispensed to waste (This is to prevent contamination of the cycling mixture by the required line diluent which contains phosphate buffer which would slow the reaction by complexing the calcium). The mixture is incubated for 15 min at 35° C in the instrument, then 40uL Chromophore/Fluorophore/HRPO reagent and
- Example 7 690uL line diluent are added. The mixture is incubated for 4 min then the fluorescence intensity is measured and the data transferred to a file for analysis. The measured fluorescence intensity decreases with increasing peroxide-generated color, and so can be used with appropriate calibrators to determine the amount of glycerol-3 -phosphate, and by extension the amount of LPA originally in the sample.
- the test can be run without lysophospholipase in the Lipase/Cycling Enzyme reagent so as to determine the background glycerol-3-phosphate.
- Figure 9 shows the results of applying the above protocol to LPA standards ranging from O to lOuM.
- the efficiency of cycling may be increased by covalently linking the cycling enzyme, G3P oxidase and G3P dehydrogenese. Since the product of one is the substrate of the other, the linkage of the two would assure availability of the appropriate enzyme in the vicinity of its substrate. Covalent linkage of the two may be carried out by methods well known in the art.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002389832A CA2389832A1 (en) | 1999-11-04 | 2000-11-02 | Improved automated lpa assay and methods of detecting cancer |
JP2001535596A JP2003530081A (en) | 1999-11-04 | 2000-11-02 | Improved automated LPA test and cancer detection method |
AU14579/01A AU1457901A (en) | 1999-11-04 | 2000-11-02 | Improved automated lpa assay and methods of detecting cancer |
EP00976865A EP1238099A2 (en) | 1999-11-04 | 2000-11-02 | Automated lysophospholipid assay and methods of detecting cancer |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16353499P | 1999-11-04 | 1999-11-04 | |
US60/163,534 | 1999-11-04 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001032916A2 true WO2001032916A2 (en) | 2001-05-10 |
WO2001032916A3 WO2001032916A3 (en) | 2002-07-11 |
Family
ID=22590455
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/030280 WO2001032916A2 (en) | 1999-11-04 | 2000-11-02 | Automated lysophospholipid assay and methods of detecting cancer |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1238099A2 (en) |
JP (1) | JP2003530081A (en) |
AU (1) | AU1457901A (en) |
CA (1) | CA2389832A1 (en) |
WO (1) | WO2001032916A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6500633B1 (en) | 2000-04-26 | 2002-12-31 | Atairgin Technologies, Inc. | Method of detecting carcinomas |
EP1439851A2 (en) * | 2001-10-31 | 2004-07-28 | Millennium Pharmaceuticals, Inc. | Methods and compositions for the treatment and diagnosis of cellular proliferation disorders using 54394 |
US11543412B2 (en) | 2015-05-13 | 2023-01-03 | Thompson Surface Innovations Corporation | Biosensors and methods for detection of lysophosphatidic acid for signaling of ovarian cancer |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8158124B2 (en) * | 2007-05-30 | 2012-04-17 | Lpath, Inc. | Compositions and methods for binding lysophosphatidic acid |
WO2023190714A1 (en) * | 2022-03-31 | 2023-10-05 | 富士フイルム株式会社 | Method for measuring lysophospholipase d activity, sensitivity enhancement agent for lysophospholipase d activity measurement, composition, and kit |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4704365A (en) * | 1986-02-24 | 1987-11-03 | Abbott Laboratories | Composition and method for stabilization of dinucleotides |
US5122454A (en) * | 1987-03-20 | 1992-06-16 | Toyo Yozo Company, Ltd. | Assay method for lecithin-cholesterol acyltransferase |
WO2000023612A1 (en) * | 1998-10-22 | 2000-04-27 | Atairgin Technologies, Inc. | Enzymatic methods for measuring lysophospholipids and phospholipids and correlation with diseases |
-
2000
- 2000-11-02 AU AU14579/01A patent/AU1457901A/en not_active Abandoned
- 2000-11-02 JP JP2001535596A patent/JP2003530081A/en not_active Withdrawn
- 2000-11-02 WO PCT/US2000/030280 patent/WO2001032916A2/en not_active Application Discontinuation
- 2000-11-02 CA CA002389832A patent/CA2389832A1/en not_active Abandoned
- 2000-11-02 EP EP00976865A patent/EP1238099A2/en not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4704365A (en) * | 1986-02-24 | 1987-11-03 | Abbott Laboratories | Composition and method for stabilization of dinucleotides |
US5122454A (en) * | 1987-03-20 | 1992-06-16 | Toyo Yozo Company, Ltd. | Assay method for lecithin-cholesterol acyltransferase |
WO2000023612A1 (en) * | 1998-10-22 | 2000-04-27 | Atairgin Technologies, Inc. | Enzymatic methods for measuring lysophospholipids and phospholipids and correlation with diseases |
Non-Patent Citations (2)
Title |
---|
HIRASHIMA Y ET AL: "Continuous spectrophotometric assay of phospholipase A2 activity hydrolyzing plasmalogens using coupling enzymes." ANALYTICAL BIOCHEMISTRY, (1989 JAN) 176 (1) 180-4., XP001001437 * |
HIRASHIMA Y ET AL: "Fluorimetric coupled enzyme assay for lysoplasmalogenase activity in liver." BIOCHEMICAL JOURNAL, (1989 JUN 1) 260 (2) 605-8., XP001001436 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6500633B1 (en) | 2000-04-26 | 2002-12-31 | Atairgin Technologies, Inc. | Method of detecting carcinomas |
EP1439851A2 (en) * | 2001-10-31 | 2004-07-28 | Millennium Pharmaceuticals, Inc. | Methods and compositions for the treatment and diagnosis of cellular proliferation disorders using 54394 |
EP1439851A4 (en) * | 2001-10-31 | 2006-05-24 | Millennium Pharm Inc | Methods and compositions for the treatment and diagnosis of cellular proliferation disorders using 54394 |
US11543412B2 (en) | 2015-05-13 | 2023-01-03 | Thompson Surface Innovations Corporation | Biosensors and methods for detection of lysophosphatidic acid for signaling of ovarian cancer |
Also Published As
Publication number | Publication date |
---|---|
EP1238099A2 (en) | 2002-09-11 |
AU1457901A (en) | 2001-05-14 |
CA2389832A1 (en) | 2001-05-10 |
JP2003530081A (en) | 2003-10-14 |
WO2001032916A3 (en) | 2002-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6500633B1 (en) | Method of detecting carcinomas | |
EP0155330B1 (en) | An improved fluorometric assay | |
US4743561A (en) | Luminescent assay with a reagent to alter transmitive properties of assay solution | |
JP4472872B2 (en) | Enzymatic methods for measuring lysophospholipids and phospholipids and their association with disease | |
JPS61146196A (en) | Method and reagent for improving photometry of h202 | |
JP2012191953A (en) | Method of pretreatment of sample for quantitating cholesterol, and method for quantitating cholesterol in specific lipoprotein using the same | |
Martinello et al. | Mechanism of ascorbic acid interference in biochemical tests that use peroxide and peroxidase to generate chromophore | |
JPH0555119B2 (en) | ||
JP2008509668A (en) | Methods and kits for assaying myeloperoxidase by enzymatic glycolate-glyoxylate cycling reaction | |
WO2001032916A2 (en) | Automated lysophospholipid assay and methods of detecting cancer | |
Chambers et al. | Determination of serum acid phosphatase in Gaucher's disease using 4-methylumbelliferyl phosphate | |
EP1255114A1 (en) | Method of measuring lipid components and method of examining renal failure | |
US20110287468A1 (en) | Methods and compositions for assaying enzymatic activity of myeloperoxidase in blood samples | |
US7374902B2 (en) | Enzyme cycling based assays for alpha-methylacyl-CoA racemase | |
JP4542234B2 (en) | Method for pretreatment of sample for determination of cholesterol and method for determination of cholesterol in specific lipoprotein using the same | |
US6448023B1 (en) | Enzyme method for detecting sphingosine-1-phosphate (S1P) | |
Belville et al. | Prostatic acid phosphatase by radioimmunoassay tumor marker in bone marrow | |
JPS59140899A (en) | Novel method for determination of substrate with oxidase | |
Joshi et al. | Significance of detection of free/total PSA ratio and other biochemical parameters in patients with BPH, carcinoma prostate and its clinicopathologic correlation | |
JPH0662521B2 (en) | Novel choline derivative and method for assaying serum cholinesterase activity using the same | |
JP3981190B2 (en) | Cholesterol determination method and reagent for determination | |
JPS6123998B2 (en) | ||
WO2023190714A1 (en) | Method for measuring lysophospholipase d activity, sensitivity enhancement agent for lysophospholipase d activity measurement, composition, and kit | |
JPH0650997B2 (en) | New method for measuring cholinesterase activity | |
JPS61173799A (en) | Method of determining activity of substrate or enzyme |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2389832 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000976865 Country of ref document: EP |
|
ENP | Entry into the national phase in: |
Ref country code: JP Ref document number: 2001 535596 Kind code of ref document: A Format of ref document f/p: F |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWP | Wipo information: published in national office |
Ref document number: 2000976865 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000976865 Country of ref document: EP |